NO2785538T3 - - Google Patents

Info

Publication number
NO2785538T3
NO2785538T3 NO12794266A NO12794266A NO2785538T3 NO 2785538 T3 NO2785538 T3 NO 2785538T3 NO 12794266 A NO12794266 A NO 12794266A NO 12794266 A NO12794266 A NO 12794266A NO 2785538 T3 NO2785538 T3 NO 2785538T3
Authority
NO
Norway
Application number
NO12794266A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO2785538T3 publication Critical patent/NO2785538T3/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027New breeds of vertebrates
    • A01K67/0275Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278Humanized animals, e.g. knockin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/5406IL-4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082Supracellular entities, e.g. tissue, organisms
    • G01N33/5088Supracellular entities, e.g. tissue, organisms of vertebrates
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00Modified animals
    • A01K2207/15Humanized animals
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/07Animals genetically altered by homologous recombination
    • A01K2217/072Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/20Animal model comprising regulated expression system
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00Animals characterised by species
    • A01K2227/10Mammal
    • A01K2227/105Murine
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00Animals characterised by purpose
    • A01K2267/01Animal expressing industrially exogenous proteins
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00Animals characterised by purpose
    • A01K2267/03Animal model, e.g. for test or diseases
    • A01K2267/035Animal model for multifactorial diseases
    • A01K2267/0368Animal model for inflammation
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00Animals characterised by purpose
    • A01K2267/03Animal model, e.g. for test or diseases
    • A01K2267/0393Animal model comprising a reporter system for screening tests
NO12794266A 2014-05-07 2012-11-22 NO2785538T3 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461989757P 2014-05-07 2014-05-07

Publications (1)

Publication Number Publication Date
NO2785538T3 true NO2785538T3 (fr) 2018-08-04

Family

ID=53284509

Family Applications (1)

Application Number Title Priority Date Filing Date
NO12794266A NO2785538T3 (fr) 2014-05-07 2012-11-22

Country Status (25)

Country Link
US (7) US9565841B2 (fr)
EP (3) EP3281521B1 (fr)
JP (4) JP6640740B2 (fr)
KR (2) KR102473565B1 (fr)
CN (2) CN110269047B (fr)
AU (2) AU2015255977B2 (fr)
BR (1) BR112016025745A2 (fr)
CA (2) CA3207834A1 (fr)
CY (2) CY1119773T1 (fr)
DK (2) DK3027015T3 (fr)
ES (2) ES2656529T3 (fr)
HR (2) HRP20211455T1 (fr)
HU (2) HUE055860T2 (fr)
IL (3) IL248358B2 (fr)
LT (2) LT3281521T (fr)
MX (1) MX370672B (fr)
NO (1) NO2785538T3 (fr)
PH (1) PH12016502058A1 (fr)
PL (2) PL3281521T3 (fr)
PT (2) PT3281521T (fr)
RS (2) RS62345B1 (fr)
RU (1) RU2703139C2 (fr)
SG (2) SG11201608570YA (fr)
SI (2) SI3281521T1 (fr)
WO (1) WO2015171861A1 (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2785538T3 (fr) 2014-05-07 2018-08-04
BR112016029650A2 (pt) 2014-06-19 2017-10-24 Regeneron Pharma roedor, polipeptídeo pd-1, célula isolada ou tecido de roedor, célula-tronco embrionária de roedor, métodos de produzir um roedor, de reduzir o crescimento de tumor em um roedor, de matar células tumorais em um roedor e de avaliar as propriedades farmacocinéticas de uma droga que direciona pd-1 humano, e, modelo de tumor de roedor?
JP6899322B2 (ja) * 2014-09-17 2021-07-07 エリコン・サーフェス・ソリューションズ・アクチェンゲゼルシャフト,プフェフィコーンOerlikon Surface Solutions Ag, Pfaeffikon 改善された耐摩耗性を有する2層コーティングされた切削工具を製造するための方法
AU2015353705C9 (en) 2014-11-24 2022-09-01 Regeneron Pharmaceuticals, Inc. Non-human animals expressing humanized CD3 complex
DK3466255T3 (da) 2014-12-05 2021-05-03 Regeneron Pharma Ikke-humane dyr med en humaniseret klynge af differentiering af 47-gen
AU2016358101B2 (en) 2015-11-20 2022-12-01 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized Lymphocyte-activation gene 3
AU2017213627B2 (en) 2016-02-04 2022-05-19 Regeneron Pharmaceuticals, Inc. Non-human animals having an engineered ANGPTL8 gene
PT3422845T (pt) * 2016-02-29 2021-08-26 Regeneron Pharma Roedores com um gene tmprss humanizado
TWI784988B (zh) 2016-12-01 2022-12-01 美商再生元醫藥公司 治療發炎症狀的方法
SG11201909457XA (en) 2017-04-13 2019-11-28 Regeneron Pharma Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding il33 and il1rl1
JP2020527332A (ja) 2017-06-12 2020-09-10 ブルーフィン バイオメディシン, インコーポレイテッド 抗−il1rap抗体および抗体薬物コンジュゲート
CN116064611A (zh) 2017-11-30 2023-05-05 瑞泽恩制药公司 包含人源化trkb基因座的非人动物
TWI829679B (zh) 2018-03-26 2024-01-21 美商再生元醫藥公司 用於測試治療藥劑之人類化囓齒動物
IL307286A (en) 2018-04-11 2023-11-01 Regeneron Pharma Methods and preparations for quantification of IL-33
JP7048051B2 (ja) 2018-07-11 2022-04-05 正徳 染井 痒みを軽減するアトピー性皮膚炎治療剤
CN116200426A (zh) 2018-07-16 2023-06-02 瑞泽恩制药公司 Ditra疾病的非人动物模型及其用途
WO2020074005A1 (fr) 2018-10-12 2020-04-16 Beijing Biocytogen Co., Ltd Animal non humain génétiquement modifié avec des gènes humains ou chimériques
CN111218425B (zh) * 2019-01-17 2022-02-08 百奥赛图(北京)医药科技股份有限公司 人源化转基因动物
SG11202108454RA (en) 2019-04-04 2021-09-29 Regeneron Pharma Non-human animals comprising a humanized coagulation factor 12 locus
EP3801011A1 (fr) 2019-06-04 2021-04-14 Regeneron Pharmaceuticals, Inc. Animaux non humains comprenant un locus ttr humanisé ayant une mutation bêta-slip et procédés d'utilisation
CN113939595A (zh) 2019-06-07 2022-01-14 瑞泽恩制药公司 包括人源化白蛋白基因座的非人动物
WO2021018198A1 (fr) * 2019-07-29 2021-02-04 Beijing Biocytogen Co., Ltd Animal non humain génétiquement modifié avec une il33 humaine ou chimérique
US20220312749A1 (en) * 2019-08-09 2022-10-06 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animal with human or chimeric il2ra
CN112779285B (zh) * 2019-11-11 2023-01-06 百奥赛图(北京)医药科技股份有限公司 人源化il-10和il-10ra基因改造动物的构建方法和应用
WO2021129766A1 (fr) * 2019-12-25 2021-07-01 江苏集萃药康生物科技股份有限公司 Modèle de souris humanisé il-15 et ses utilisations
CA3169272A1 (fr) * 2020-01-28 2021-08-05 Regeneron Pharmaceuticals, Inc. Animaux non humains comprenant un locus pnpla3 humanise et procedes d'utilisation
CN111149767B (zh) * 2020-02-24 2021-07-20 中南大学湘雅二医院 一种人源化皮肤型红斑狼疮小鼠模型的构建方法和应用
CN113527485A (zh) * 2020-04-17 2021-10-22 上海麦济生物技术有限公司 抗人白细胞介素-4受体α抗体及其制备方法和应用
CN111808882B (zh) * 2020-09-01 2020-12-29 北京百奥赛图基因生物技术有限公司 Il7r基因人源化改造的动物模型的构建方法及其应用
CN111793646B (zh) * 2020-09-08 2021-01-15 北京百奥赛图基因生物技术有限公司 Il1r1基因人源化改造的非人动物的构建方法及其应用
CN111926039B (zh) * 2020-09-23 2021-03-16 百奥赛图(北京)医药科技股份有限公司 Il-13基因人源化的非人动物的构建方法和应用
EP4262374A1 (fr) * 2020-12-21 2023-10-25 Regeneron Pharmaceuticals, Inc. Animaux non humains ayant un gène tslp humanisé, un gène récepteur tslp humanisé et/ou un gène il7ra humanisé
CN114835798B (zh) * 2021-05-28 2024-02-23 百奥赛图(北京)医药科技股份有限公司 Cd36基因人源化非人动物的构建方法及应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005183A1 (fr) * 1988-10-31 1990-05-17 Immunex Corporation Recepteurs d'interleukine-4
CA2827654C (fr) 2004-10-19 2019-04-02 Regeneron Pharmaceuticals, Inc. Methode de production d'un animal homozygote pour une modification genetique
JP2007252370A (ja) * 2006-02-22 2007-10-04 Institute Of Physical & Chemical Research Il−4初期発現系トランスジェニック非ヒト動物およびその利用
US20110016543A1 (en) * 2008-12-04 2011-01-20 Sigma-Aldrich Co. Genomic editing of genes involved in inflammation
JP2012531896A (ja) * 2009-06-29 2012-12-13 チェン,チンフェン ヒト化非ヒト哺乳動物を製造する方法
AU2010275432A1 (en) * 2009-07-24 2012-02-02 Sigma-Aldrich Co. Llc. Method for genome editing
RU2425880C2 (ru) * 2009-07-30 2011-08-10 Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН Способ получения трансгенных мышей
ES2591107T3 (es) 2009-10-06 2016-11-24 Regeneron Pharmaceuticals, Inc. Ratones modificados genéticamente e injerto
RU2730643C2 (ru) 2011-02-15 2020-08-24 Ридженерон Фармасьютикалз, Инк. Гуманизированные m-csf мыши
DK2818478T3 (en) * 2011-10-28 2017-05-22 Regeneron Pharma HUMANIZED IL-6 AND IL-6 RECEPTOR
LT3590332T (lt) 2011-10-28 2022-08-10 Regeneron Pharmaceuticals, Inc. Genetiškai modifikuotos pelės, ekspresuojančios chimerines pagrindinio audinių dermės komplekso (mhc) ii molekules
CN107254480B (zh) 2011-10-28 2021-08-10 瑞泽恩制药公司 制备主要组织相容性复合物基因修饰小鼠的方法
US8962913B2 (en) 2012-06-18 2015-02-24 Regeneron Pharmaceuticals, Inc. Humanized IL-7 rodents
ES2900342T3 (es) * 2012-08-21 2022-03-16 Sanofi Biotechnology Métodos para tratar o prevenir el asma administrando un antagonista de IL-4R
KR102594390B1 (ko) 2012-09-07 2023-10-27 예일 유니버시티 유전적으로 변형된 비-인간 동물 및 이것들의 사용 방법
CN104918483B (zh) 2012-11-05 2018-05-11 再生元制药公司 生成及使用经遗传修饰的非人动物的方法
SI2958938T1 (sl) 2013-02-20 2019-08-30 Regeneron Pharmaceuticals, Inc. Miši, ki izražajo humanizirane koreceptorje za celice T
CN105164154B (zh) 2013-02-22 2019-06-07 瑞泽恩制药公司 表达人源化主要组织相容性复合物的小鼠
JO3532B1 (ar) 2013-03-13 2020-07-05 Regeneron Pharma الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
TR201901782T4 (tr) 2013-09-23 2019-03-21 Regeneron Pharma İnsanlaştirilmiş bi̇r si̇nyal düzenleyi̇ci̇ protei̇n geni̇ne sahi̇p olan i̇nsan dişi hayvanlar.
MX2016004781A (es) 2013-10-15 2016-07-26 Regeneron Pharma Il-15 humanizada en animales.
CA2929846C (fr) 2013-11-19 2020-09-15 Regeneron Pharmaceuticals, Inc. Animaux non humains ayant un gene de facteur activant les cellules b humanise
JP6484237B2 (ja) 2013-11-19 2019-03-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. ヒト化増殖誘導リガンド遺伝子を有する非ヒト動物
DK3129400T3 (da) 2014-04-08 2020-06-08 Regeneron Pharma Ikke-humane dyr med humaniserede Fc-gamma-receptorer
CA3225091A1 (fr) 2014-05-05 2015-11-12 Regeneron Pharmaceuticals, Inc. Animaux porteurs des sequences c5 et c3 humanisees
NO2785538T3 (fr) * 2014-05-07 2018-08-04

Also Published As

Publication number Publication date
JP6640740B2 (ja) 2020-02-05
US20150320021A1 (en) 2015-11-12
JP2017514501A (ja) 2017-06-08
JP7145250B2 (ja) 2022-09-30
KR102473565B1 (ko) 2022-12-02
US11963521B2 (en) 2024-04-23
EP3027015B1 (fr) 2017-11-08
AU2015255977B2 (en) 2021-09-02
US20200022344A1 (en) 2020-01-23
SG11201608570YA (en) 2016-11-29
US10477842B2 (en) 2019-11-19
US11109578B2 (en) 2021-09-07
KR20160150637A (ko) 2016-12-30
EP3281521A1 (fr) 2018-02-14
IL248358A0 (en) 2016-11-30
BR112016025745A2 (pt) 2018-01-16
CN110269047A (zh) 2019-09-24
SG10201912354PA (en) 2020-02-27
PL3281521T3 (pl) 2022-01-03
IL304841A (en) 2023-09-01
KR102517112B1 (ko) 2023-04-03
JP6838131B2 (ja) 2021-03-03
CY1124605T1 (el) 2022-07-22
US9743647B2 (en) 2017-08-29
PH12016502058A1 (en) 2017-01-09
CA2947307C (fr) 2023-09-26
US20170311580A1 (en) 2017-11-02
AU2015255977A1 (en) 2016-11-17
CN110269047B (zh) 2021-11-02
HRP20180242T1 (hr) 2018-03-09
IL248358B2 (en) 2023-03-01
PT3027015T (pt) 2018-02-09
AU2021218060B2 (en) 2024-04-11
DK3027015T3 (en) 2018-01-22
MX370672B (es) 2019-12-19
EP3906781A1 (fr) 2021-11-10
US20180000056A1 (en) 2018-01-04
RU2016143376A3 (fr) 2018-11-22
EP3281521B1 (fr) 2021-06-30
US20210368753A1 (en) 2021-12-02
IL297105B2 (en) 2024-01-01
IL297105B1 (en) 2023-09-01
US20150320022A1 (en) 2015-11-12
PL3027015T3 (pl) 2018-04-30
IL248358B (en) 2022-11-01
JP2022171841A (ja) 2022-11-11
RS62345B1 (sr) 2021-10-29
CA3207834A1 (fr) 2015-11-12
EP3027015A1 (fr) 2016-06-08
RU2703139C2 (ru) 2019-10-15
LT3027015T (lt) 2018-01-25
DK3281521T3 (da) 2021-09-20
US9565841B2 (en) 2017-02-14
CA2947307A1 (fr) 2015-11-12
SI3281521T1 (sl) 2021-11-30
JP2021087434A (ja) 2021-06-10
LT3281521T (lt) 2021-09-27
RU2019131253A (ru) 2019-12-06
MX2016014563A (es) 2017-02-23
US20230027494A1 (en) 2023-01-26
JP2020058379A (ja) 2020-04-16
ES2656529T3 (es) 2018-02-27
WO2015171861A1 (fr) 2015-11-12
CN106470545B (zh) 2019-08-20
AU2021218060A1 (en) 2021-09-09
HRP20211455T1 (hr) 2022-01-07
US10588298B2 (en) 2020-03-17
PT3281521T (pt) 2021-09-16
RS57073B1 (sr) 2018-06-29
HUE055860T2 (hu) 2021-12-28
ES2887852T3 (es) 2021-12-28
SI3027015T1 (en) 2018-02-28
CY1119773T1 (el) 2018-06-27
CN106470545A (zh) 2017-03-01
KR20220165814A (ko) 2022-12-15
IL297105A (en) 2022-12-01
RU2016143376A (ru) 2018-06-09
HUE038028T2 (hu) 2018-09-28

Similar Documents

Publication Publication Date Title
BR112014017635A2 (fr)
BR112014017614A2 (fr)
BR112014017625A2 (fr)
NO2785538T3 (fr)
BR112014017659A2 (fr)
BR112014017646A2 (fr)
BR112014017638A2 (fr)
BR112014018648A2 (fr)
BR112014024237A2 (fr)
BR112014018115A2 (fr)
BR112014017634A2 (fr)
BR112014017609A2 (fr)
BR112014017673A2 (fr)
BR112014017644A2 (fr)
BR112014017647A2 (fr)
BR112014017618A2 (fr)
BR112014017630A2 (fr)
BR112014017652A2 (fr)
BR112014017621A2 (fr)
BR112014017627A2 (fr)
BR112014017623A2 (fr)
BR112014025138A2 (fr)
BR112014023519A2 (fr)
BR112014018787A2 (fr)
BR112014017622A2 (fr)